

MIRAGEN THERAPEUTICS, INC.
Form DEFA14A
May 03, 2019

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934
(Amendment No.)

Filed by the Registrant ☒ x

Filed by a Party other than the Registrant ☐ o

Check the appropriate box:

- ☐ o Preliminary Proxy Statement
- ☐ o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
- ☐ o Definitive Proxy Statement
- ☒ x Definitive Additional Materials
- ☐ o Soliciting Material Pursuant to §240.14a-12

Miragen Therapeutics, Inc.
(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement if Other Than the Registrant)

Payment of Filing Fee (Check the appropriate box):

- ☒ x No fee required.
 - ☐ o Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
- (1) Title of each class of securities to which transaction applies:

- Aggregate number of securities to which transaction applies:
- (2)

- (3) Per unit price or other

underlying
value of
transaction
computed
pursuant to
Exchange
Act Rule
0-11 (Set
forth the
amount on
which the
filing fee is
calculated
and state
how it was
determined):

Proposed
maximum
(4) aggregate
value of
transaction:

(5) Total fee
paid:

Fee paid
previously
o with
preliminary
materials:

o Check box if
any part of
the fee is
offset as
provided by
Exchange
Act Rule
0-11(a)(2)
and identify
the filing for
which the
offsetting fee
was paid
previously.
Identify the
previous
filing by
registration
statement

number, or
the Form or
Schedule and
the date of its
filing.

Amount

(1) Previously
Paid:

Form,
Schedule or

(2) Registration
Statement
No.:

(3) Filing Party:

(4) Date Filed:
